Gland Pharma Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
Gland Pharma has a total shareholder equity of ₹87.2B and total debt of ₹3.7B, which brings its debt-to-equity ratio to 4.3%. Its total assets and total liabilities are ₹106.6B and ₹19.4B respectively. Gland Pharma's EBIT is ₹9.3B making its interest coverage ratio 34.7. It has cash and short-term investments of ₹18.4B.
Belangrijke informatie
4.3%
Verhouding schuld/eigen vermogen
₹3.72b
Schuld
| Rente dekkingsratio | 34.7x |
| Contant | ₹18.39b |
| Aandelen | ₹87.24b |
| Totaal verplichtingen | ₹19.37b |
| Totaal activa | ₹106.61b |
Recente financiële gezondheidsupdates
Geen updates
Recent updates
Analyse van de financiële positie
Kortlopende schulden: 543245's short term assets (₹56.5B) exceed its short term liabilities (₹14.0B).
Langlopende schulden: 543245's short term assets (₹56.5B) exceed its long term liabilities (₹5.4B).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 543245 has more cash than its total debt.
Schuld verminderen: 543245's debt to equity ratio has increased from 0.2% to 4.3% over the past 5 years.
Schuldendekking: 543245's debt is well covered by operating cash flow (267.8%).
Rentedekking: 543245's interest payments on its debt are well covered by EBIT (34.7x coverage).